Drug Profile
Vobramitamab duocarmazine - MacroGenics
Alternative Names: Anti-B7-H3 antibody drug conjugate - MacroGenics; B7-H3; MGC 018Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator MacroGenics
- Class Antineoplastics; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Prostate cancer
- Phase I Solid tumours
- Preclinical Neuroblastoma
Most Recent Events
- 31 Dec 2023 MacroGenics plans a phase I trial for Solid tumour in mid of 2024 (Parenteral)
- 06 Nov 2023 Macrogenics plans a phase I/II trial for Solid tumours (Combination therapy) in USA
- 13 Jun 2023 Phase-II/III clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in France, Belgium, Italy, United Kingdom, South Korea, Poland, Spain, Australia (IV) (NCT05551117)